All PlansCoverageMedium impact
Myocardial Sympathetic Innervation Imaging in Individuals with Heart Failure
Blue Cross & Blue Shield of Mississippi·MS · Nuclear Medicine, Radiology, Cardiology·Medical Policy
We identified it
Jun 20, 2026
Summary
MIBG myocardial imaging for heart failure patients remains classified as investigational and not covered. This policy clarifies that the imaging is not considered medically necessary despite FDA approval for assessing sympathetic innervation in NYHA class II/III heart failure patients with LVEF <35%.
Action Required
Immediately: Billing team should continue to deny/not bill for MIBG myocardial imaging (iodine 123 meta-iodobenzylguanidine) for heart failure patients as it remains investigational. Inform providers that this imaging is not covered despite FDA approval. Update denial reason codes to reference policy A.6.01.56 for any claims submitted.